Santa Ana Bio Raises $168M in Funding for Precision Immunology Therapeutics and Expansion

Santa Ana Bio raises $168M in Series A and B Funding

Santa Ana Bio (Linkedin), a precision immunology company, has secured a total of $168 million in combined Series A and B funding. With a focus on developing therapeutics for autoimmune and inflammatory diseases, Santa Ana Bio aims to revolutionize precision medicine through their innovative multi-omics platform.

Funding Amount: $168 million

Industry: Biotechnology Research

Employee Count: 11-50

CEO: Alex Urrutia (CEO Linkedin)

What Santa Ana Bio needs to buy: Santa Ana Bio is seeking partnerships with research organizations, manufacturers, and regulatory experts to advance their therapeutics pipeline, ensure reliable production and supply chain, and navigate the complex regulatory landscape in the biotechnology industry. Companies specializing in research and development services, manufacturing, and regulatory compliance are ideal partners for Santa Ana Bio's ambitious goals.